CoChat
Sign Up
Cited by 55

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice

Roubtsova, Anna, Chamberland, Ann, Marcinkiewicz, Jadwiga, Essalmani, Rachid, Fazel, Ali, Bergeron, John J., Seidah, Nabil G., Prat, Annik·2015·Journal of Lipid Research
DOI 10.1194/jlr.m061952
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.m061952

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In Pcsk9-knockout mice, LDLR protein levels at the cell surface of hepatocytes and in whole tissue are increased, while ASGR1 levels are not affected.

    “The data showed that, although LDLR protein levels at the cell surface of hepatocytes (IHC) and in whole tissue (WB) were increased in Pcsk9-KO livers, in accordance with (21), those of ASGR1 were not affected.”

    From Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin (2021) · cites this paper as [21]

    In “LDLR subcellular distribution is affected by sex in PCSK9 KO livers” (page unavailable), the paper reports increased LDLR in liver extracts from both sexes, but increased hepatocyte-surface LDLR only in knockout males, not females. The citation is attached to the LDLR comparison; the sentence presents the ASGR1 result as the citing authors’ own data, so ASGR1 is not assessed as a claim attributed to this source. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 39

  1. Seidah, 2012, The biology and therapeutic targeting of the proprotein convertases, Nat. Rev. Drug Discov., 11, 367, 10.1038/nrd3699 · DOI · Paper page
  2. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet., 34, 154, 10.1038/ng1161 · DOI · Paper page
  3. Maxwell, 2004, Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype, Proc. Natl. Acad. Sci. USA., 101, 7100, 10.1073/pnas.0402133101 · DOI · Paper page
  4. Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol, J. Biol. Chem., 279, 48865, 10.1074/jbc.M409699200 · DOI · Paper page
  5. Denis, 2012, Gene inactivation of PCSK9 reduces atherosclerosis in mice, Circulation., 125, 894, 10.1161/CIRCULATIONAHA.111.057406 · DOI · Paper page
  6. Guella, 2010, Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population, J. Lipid Res., 51, 3342, 10.1194/jlr.M010009 · DOI
  7. Huang, 2012, Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk, Genome Med., 4, 57, 10.1186/gm358 · DOI
  8. Zhao, 2006, Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote, Am. J. Hum. Genet., 79, 514, 10.1086/507488 · DOI
  9. Hooper, 2007, The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population, Atherosclerosis., 193, 445, 10.1016/j.atherosclerosis.2006.08.039 · DOI
  10. Cariou, 2009, PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia, Arterioscler. Thromb. Vasc. Biol., 29, 2191, 10.1161/ATVBAHA.109.194191 · DOI
  11. Seidah, 2013, Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies, Curr. Pharm. Des., 19, 3161, 10.2174/13816128113199990313 · DOI
  12. Naureckiene, 2003, Functional characterization of Narc 1, a novel proteinase related to proteinase K, Arch. Biochem. Biophys., 420, 55, 10.1016/j.abb.2003.09.011 · DOI
  13. Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc. Natl. Acad. Sci. USA., 100, 928, 10.1073/pnas.0335507100 · DOI · Paper page
  14. Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat. Struct. Mol. Biol., 14, 413, 10.1038/nsmb1235 · DOI · Paper page
  15. Kwon, 2008, Molecular basis for LDL receptor recognition by PCSK9, Proc. Natl. Acad. Sci. USA., 105, 1820, 10.1073/pnas.0712064105 · DOI · Paper page
  16. Poirier, 2009, Dissection of the endogenous cellular pathways of PCSK9-induced LDLR degradation: evidence for an intracellular route, J. Biol. Chem., 284, 28856, 10.1074/jbc.M109.037085 · DOI · Paper page
  17. Timms, 2004, A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree, Hum. Genet., 114, 349, 10.1007/s00439-003-1071-9 · DOI
  18. Zaid, 2008, Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration, Hepatology., 48, 646, 10.1002/hep.22354 · DOI · Paper page
  19. Mbikay, 2010, PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities, FEBS Lett., 584, 701, 10.1016/j.febslet.2009.12.018 · DOI
  20. Langhi, 2009, PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion, Biochem. Biophys. Res. Commun., 390, 1288, 10.1016/j.bbrc.2009.10.138 · DOI
  21. Roubtsova, 2011, Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue, Arterioscler. Thromb. Vasc. Biol., 31, 785, 10.1161/ATVBAHA.110.220988 · DOI · Paper page
  22. Ishibashi, 1993, Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery, J. Clin. Invest., 92, 883, 10.1172/JCI116663 · DOI · Paper page
  23. Hubbard, 1983, Isolation of rat hepatocyte plasma membranes. I. Presence of the three major domains, J. Cell Biol., 96, 217, 10.1083/jcb.96.1.217 · DOI
  24. Kay, 1986, Epidermal growth factor receptor kinase translocation and activation in vivo, J. Biol. Chem., 261, 8473, 10.1016/S0021-9258(19)83935-2 · DOI
  25. Widnell, 1968, Partial purification of a lipoprotein with 5′-nucleotidase activity from membranes of rat liver cells, Proc. Natl. Acad. Sci. USA., 61, 1050, 10.1073/pnas.61.3.1050 · DOI
  26. Ames, 1960, The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid, J. Biol. Chem., 235, 769, 10.1016/S0021-9258(19)67936-6 · DOI
  27. Bergeron, 1978, Intracellular polypeptide hormone receptors. The demonstration of specific binding sites for insulin and human growth hormone in Golgi fractions isolated from the liver of female rats, J. Biol. Chem., 253, 4058, 10.1016/S0021-9258(17)34798-1 · DOI
  28. Rashid, 2005, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, Proc. Natl. Acad. Sci. USA., 102, 5374, 10.1073/pnas.0501652102 · DOI · Paper page
  29. Ngo Sock, 2014, LDL receptor and Pcsk9 transcripts are decreased in liver of ovariectomized rats: effects of exercise training, Horm. Metab. Res., 46, 550, 10.1055/s-0034-1370910 · DOI
  30. Lakoski, 2009, Genetic and metabolic determinants of plasma PCSK9 levels, J. Clin. Endocrinol. Metab., 94, 2537, 10.1210/jc.2009-0141 · DOI · Paper page
  31. Ghosh, 2015, Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol, J. Lipid Res., 56, 463, 10.1194/jlr.M055780 · DOI
  32. Ooi, 2015, Relationship between testosterone, estradiol and circulating PCSK9: cross-sectional and interventional studies in humans, Clin. Chim. Acta., 446, 97, 10.1016/j.cca.2015.03.036 · DOI
  33. Li, 2001, Requirement of Sp1 and estrogen receptor alpha interaction in 17beta-estradiol-mediated transcriptional activation of the low density lipoprotein receptor gene expression, Endocrinology., 142, 1546, 10.1210/endo.142.4.8096 · DOI
  34. Bruning, 2003, Estrogen receptor-alpha and Sp1 interact in the induction of the low density lipoprotein-receptor, J. Steroid Biochem. Mol. Biol., 86, 113, 10.1016/S0960-0760(03)00263-2 · DOI
  35. Chen, 1990, NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor, J. Biol. Chem., 265, 3116, 10.1016/S0021-9258(19)39742-X · DOI · Paper page
  36. Zelcer, 2009, LXR regulates cholesterol uptake through IDOL-dependent ubiquitination of the LDL receptor, Science., 325, 100, 10.1126/science.1168974 · DOI · Paper page
  37. Frasor, 2003, Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype, Endocrinology., 144, 4562, 10.1210/en.2003-0567 · DOI
  38. Cerillo, 1998, The oestrogen receptor regulates NFkappaB and AP-1 activity in a cell-specific manner, J. Steroid Biochem. Mol. Biol., 67, 79, 10.1016/S0960-0760(98)00078-8 · DOI
  39. Parker, 2013, Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression, J. Lipid Res., 54, 2400, 10.1194/jlr.M038331 · DOI

Cited by

Sorted by citations

Metadata

Authors
Roubtsova, A., Chamberland, A., Marcinkiewicz, J., Essalmani, R., Fazel, A., Bergeron, J. J., Seidah, N. G., & Prat, A.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2015-11
Volume
56
Issue
11
Pages
2133-2142
ISSN
0022-2275
DOI
10.1194/jlr.m061952
Cited by
55
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review